[
    "{\"step_by_step_thinking\": \"Based on the information provided in the relevant documents, losartan was tested in a double-blind, randomized controlled trial for its ability to reduce brain volume loss in patients with mild-to-moderate Alzheimer's disease. The trial involved 211 participants who were randomly assigned to receive either losartan or placebo for 12 months. The primary outcome, change in whole brain volume, was measured using MRI. The results showed that losartan was not effective in reducing the rate of brain atrophy compared to placebo. Therefore, the answer is B. no.\", \"answer_choice\": \"B\"}"
]